Active not recruiting
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease
I8G-MC-LMDC - ClinicalTrials.gov - NCT03518073
The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).
How long will I be in the trial?
The study will last about 128 weeks and may include up to 27 visits.
Active not recruiting
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease
I8G-MC-LMDC - ClinicalTrials.gov - NCT03518073
The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).
How long will I be in the trial?
The study will last about 128 weeks and may include up to 27 visits.
Key Requirements
Age :
60-85
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
60-85
Sex
All
Participants must
Participants must have gradual and progressive change in memory function for >6 months
Participants must have a family member or close friend who is with participant at least 10 hours per week and can attend study appointments
Participants must NOT
Participants must not have significant neurological disease affecting the nervous system, other than AD, that affects cognition or may affect completion of the study
Participants must not have serious or unstable illness that could interfere with the analysis of the study or have a life expectancy <24 months
Participants must not have history of cancer within the last 5 years with the exception of certain types of skin, cervical, prostate, and other cancers that are not likely to recur or spread
Participants must not have serious risk for suicide
Participants must not have history of drug or alcohol use disorder within the last 2 years
Participants must not have multiple severe drug allergies
Participants must not have HIV, Hepatitis B or Hepatitis C
Trial Summary
Conditions the trial is for
Early Symptoms of Alzheimer's Disease
What the trial is testing?
LY3303560, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
285
Trial Dates
April 2018 - October 2021
Trial Phase
2
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
60-85
Sex
All
Participants must
Participants must have gradual and progressive change in memory function for >6 months
Participants must have a family member or close friend who is with participant at least 10 hours per week and can attend study appointments
Participants must NOT
Participants must not have significant neurological disease affecting the nervous system, other than AD, that affects cognition or may affect completion of the study
Participants must not have serious or unstable illness that could interfere with the analysis of the study or have a life expectancy <24 months
Participants must not have history of cancer within the last 5 years with the exception of certain types of skin, cervical, prostate, and other cancers that are not likely to recur or spread
Participants must not have serious risk for suicide
Participants must not have history of drug or alcohol use disorder within the last 2 years
Participants must not have multiple severe drug allergies
Participants must not have HIV, Hepatitis B or Hepatitis C
Trial Summary
Conditions the trial is for
Early Symptoms of Alzheimer's Disease
What the trial is testing?
LY3303560, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
285
Trial Dates
April 2018 - October 2021
Trial Phase
2
Not the right fit? Sign up to receive updates on new Early Symptoms of Alzheimer's Disease trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Early Symptoms of Alzheimer's Disease Resources
